骨髓增生异常综合征和再生障碍性贫血患者骨髓CD34+细胞测定

 目的 检测骨髓增生异常综合征（MDS）和再生障碍性贫血（AA）患者骨髓CD+34细胞占单个核细胞（MNC）的比率，以探讨二者可能的发病机制。方法 用流式细胞术（FCM）检测22例MDS患者、13例AA患者及12例非血液病患者骨髓CD+34细胞占MNC的比率。结果 AA组与对照组、AA组与MDS-RA组、AA组与MDS-RAEB组、MDS-RA组与MDS-RAEB组的骨髓MNC中CD+34细胞的比率的比较差异有统计学意义（P＜0.05）。大多数重型AA（SAA）患者（3／4）及很少慢性AA（CAA）患者（1／9）的骨髓MNC中的CD+34细胞的比率＜0.1 %。结论 骨髓CD+34细胞的检测有助于判断AA患者病情及MDS患者的预后，亦可用于鉴别AA和MDS。

The determination of CD34 positive cells in bone marrow of the patients with myelodysplastic syndrome and aplastic anemia

Objective To detect the ratio of CD+34 cells in bone marrow mononuclear cells of the pa－tients with myelodysplastic syndrome (MDS) and aplastic anemia (AA), so to explore different pathogenesis between MDS and AA. Methods To detect the ratio of CD+34 cells in bone marrow mononuclear cells of 22 MDS patients, 13 AA patients and 12 normal subjects by flow cytometry (FCM). Results There was signifi－cant difference according to the ratio of CD+34 cells in mononuclear cells of bone marrow between AA group and control group. AA group and MDS-RA group, AA group and MDS-RAEB group, MDS-RA group and MDS-RAEB group (P ＜0.05). The ratio of CD+34 cells in mononuclear cells of bone marrow was less than 0.1% in the majority of SAA patients (3/4) while it was seldom less than 0.1 % in CAA patients (1/9). Conclusion The determination of CD+34 cells can be used to judge pathogenetic condition of AA patients and the prognosis of MDS patients. It also is helpful to distinguish AA and MDS.